Form 4: Harmony Biosciences Director Acquires Stock Options
SEC Form 4 Filing
R. Mark Graf, a director at Harmony Biosciences Holdings, Inc., acquired 6,336 stock options on May 29, 2024.
Summary
- On May 29, 2024, R. Mark Graf, a director of Harmony Biosciences Holdings, Inc., acquired 6,336 stock options.
- The options have an exercise price of $29.33.
- The stock options will vest fully on the earlier of May 29, 2025, or the date of the next annual meeting following the grant date, contingent upon continued service.
- The expiration date for these options is May 29, 2034.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to stock option grants, and doesn't inherently indicate positive or negative sentiment. It's a neutral event.
Industry Context
This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.
Stakeholder Impact
- The acquisition of stock options by a director could be perceived positively by shareholders, as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 05/29/2024 | Date of transaction: R. Mark Graf acquired 6,336 stock options. |
| 05/29/2025 | Earliest vesting date for the stock options, contingent on continued service. |
| 05/29/2034 | Expiration date of the stock options. |
| 05/31/2024 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.